Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea

Drugs of Today

Volumn 49, Issue 4, 2013, Pages 239-252

  Yeo, Q M ^a   Crutchley, R ^b   Cottreau, J ^b   Tucker, A ^b   Carey, K W ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

CFTR gene; Cholera; Clostridium difficile; Crofelemer; Diarrhea; HIV AIDS

Indexed keywords

BISMUTH SALICYLATE; CALCIUM ACTIVATED CHLORIDE CHANNEL; CHOLERA TOXIN; CROFELEMER; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLYCOPROTEIN GP 120; HAPTOCORRIN; RITONAVIR; TRANSACTIVATOR PROTEIN; ZINC;

ABDOMINAL PAIN; APOPTOSIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CHOLERA; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; DRUG RELEASE; DRUG TOLERABILITY; ENTEROPATHY; ENTEROTOXIGENIC ESCHERICHIA COLI; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GIARDIASIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS DIARRHEA; INTESTINE EPITHELIUM; IRRITABLE COLON; LONG TERM CARE; NONHUMAN; NOROVIRUS INFECTION; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; ROTAVIRUS INFECTION; SECRETORY DIARRHEA; SINGLE DRUG DOSE; TRAVELLER DIARRHEA; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

CFTR GENE; CHOLERA; CLOSTRIDIUM DIFFICILE; CROFELEMER; DIARRHEA; HIV/AIDS;

ANIMALS; ANTIDIARRHEALS; DIARRHEA; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; PROANTHOCYANIDINS;

EID: 84877796593     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2013.49.4.1947253     Document Type: Article

References (51)

1. Tradtrantip, L, Namkung, W., Verkman, A.S. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol 2010, 77(1): 69-78.
2. Cottreau, J., Tucker, A., Crutchley, R., Garey, K.W. Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol 2012, 6(1): 17-23.
3. Diarrhoeal disease. World Health Organization, August 2009. http://www.who.int/mediacentre/factsheets/fs330/en/index.html. Accessed November 26, 2012.
4. Sem rad, CE. Approach to the patient with diarrhea and malabsorption. In: Goldman's Cecil Medicine. Vol. 1. 24 ed. L.S. Goldman, A.I. (Ed.). Saunders: Philadelphia 2012, 895-913.
5. Berkes, J., Viswanathan, V.K., Savkovic, S.D., Hecht, G. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 2003, 52(3): 439-51.
6. Schiller, L.R., Sellin, J.H. Diarrhea. In: Feldman: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Vol. 1. M.H. Sleisenger, Fordtran, J.S. (Ed.). Saunders: Philadelphia 2010, 211-32.
7. Hodges, K., Gill, R. Infectious diarrhea: Cellular and molecular mechanisms. Gut Microbes 2010, 1(1): 4-21.
8. Udayakumar, N., Giannella, R.A. Definition, epidemiology, pathophysiology, clinical classification, and differential diag-nosis of diarrhea. In: Diarrhea: Diagnostic and Therapeutic Advances. S. Guandalini, Vaziri, H. (Ed.). Humana Press: New York 2011, 1-32.
9. Navaneethan, U., Giannella, RA. Mechanisms of infectious diarrhea. Nat Clin Pract Gastroenterol Hepatol 2008, 5(11): 637-47.
10. Sandle, G.I. Infective and inflammatory diarrhoea: mechanisms and opportunities for novel therapies. Curr Opin Pharmacol 2011, 11(6): 634-9.
11. Troeger, H., Loddenkemper, C, Schneider, T. et al. Structural and functional changes of the duodenum in human norovirus infection. Gut 2009, 58(8): 1070-7.
12. Alcantara, C, Stenson, W.F., Steiner, TS., Guerrant, R.L. Role of inducible cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in an animal model. J Infect Dis 2001, 184(5): 648-52.
13. Troeger, H., Epple, HJ., Schneider, T. et al. Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum. Gut 2007, 56(3): 328-35.
14. MacArthur, R.D., DuPont, H.L. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis 2012, 55(6): 860-7.
15. Call, S.A., Heudebert, G., Saag, M., Wilcox, CM. The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3. Am J Gastroenterol 2000, 95(11): 3142-6.
16. Monkemuller, K.E., Call, S.A., Lazenby, A.J., Wilcox, CM. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. Am J Gastroenterol 2000, 95(2): 457-62.
17. Bode, H., Lenzner, L, Kraemer, O.H. et al. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apopto-sis and decrease barrier function in human intestinal epithelial cells. AntivirTher 2005, 10(5): 645-55.
18. Rufo, P.A., Lin, P.W., Andrade, A. et al. Diarrhea-associated HIV-lAPIs potentiate muscarinic activation of CI-secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. Am J Physiol Cell Physiol 2004, 286(5): C998-C1008.
19. Canani, R.B., Cirillo, P., Mallardo, G. et al. Effects ofHIV-1 Tat protein on ion secretion and on cell proliferation in human intestinal epithelial cells. Gastroenterology 2003, 124(2): 368-76.
20. Braga Neto, M.B., Aguiar, C.V., Maciel, J.C et al. Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. BMC Gastroenterol 2010, 10: 90.
21. Wald, A. Irritable bowel syndrome. In: Diarrhea: Diagnostic and Therapeutic Advances. S. Guandalini, Vaziri, H. (Ed.). Humana Press: New York 2011, 325-40.
22. Ta Hey, N.J. Irritable bowel syndrome. In: Feldman: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. M.H. Sleisenger, Fordtran, J.S. (Ed.). Saunders: Philadelphia 2010, 2091-104.
23. Mangel, A.W., Chaturvedi, P. Evaluation of crofelemerin the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008, 78(4): 180-6.
24. National Center for Immunization and Respiratory Diseases: Division of Bacterial Diseases. Traveler's diarrhea. Department of Health and Human Services, Centers for Disease Control and Prevention, http://www.cdc.gov/nci- dod/dbmd/diseaseinfo/travelersdiarrhea-g.htm#causes. Accessed November 28, 2012.
25. Musher, D.M., Musher, B.L. Contagious acute gastrointestinal infections. N Engl J Med 2004, 351(23): 2417-27.
26. Kufelnicka, A.M., Kirn, T.J. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. Clin Infect Dis 2011, 52(12): 1451-7.
27. Lima, A.A., Lyerly, D.M., Wilkins, TD., Innes, DJ., Guerrant, R.L. Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun 1988, 56(3): 582-8.
28. Moore, R., Pothoulakis, C, LaMont, J.T, Carlson, S., Madara, J.L. C difficile toxin A increases intestinal permeability and induces CI-secretion. Am J Physiol 1990, 259(2, Pt. 1): G165-72.
29. Giannella, R.A. Infectious enteritis and proctocolitis and bacterial food poisoning. In: Feldman: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. M.H. Sleisenger, Fordtran, J.S. (Ed.). Saunders: Philadelphia 2010, 1843-87.
30. Spruill, W.J., Wade, W.E. Diarrhea, constipation, and irritable bowel syndrome In: Pharmacotherapy: A Pathophysiologic Approach. 7th ed. J.T. Dipiro, Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, LM. (Ed.). McGraw-Hill: 2008, 617-32.
31. Hoque, K.M., Binder, H.J. Zinc in the treatment of acute diarrhea: current status and assessment. Gastroenterology 2006, 130(7): 2201-5.
32. Berni Canani, R., Secondo, A., Passariello, A. et al. Zinc inhibits calcium-mediated and nitric oxide-mediated ion secretion in human enterocytes. Eur J Pharmacol 2010, 626(2-3): 266-70.
33. Fischer, H., Machen, TE., Widdicombe, J.H., Carlson, T.J., King, S.R., Chow, J.W., Illek, B. A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells. J Ethnopharmacol 2004, 93(2-3): 351-7.
34. King, S.R., Chaturvedi, P. The development of crofelemer: Connecting ethnobotany conservation, biocultural diversity, global public health and indigenous knowledge. Int Congr Nat Prod Res (July 28-Aug 1, New York) 2012, Abst IL33.
35. Ubillas, R., Jolad, S.D., Bruening, R.C. et al. SP-303, an antiviral oligomeric proanthocyanidin from the latex of Croton lechleri (Sangre de Drago). Phytomedicine 1994,1(2): 77-106.
36. Gabriel, S.E., Davenport, S.E., Steagall, R.J., Vimal, V., Carlson, T, Rozhon, E.J. A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion. Am J Physiol 1999, 276(1, Pt. 1): G58-63.
37. Wyde, P., Meyerson, L., Gilbert, B. An in vitro evaluation of the antiviral activity of SP-303, an Euphorbiaceae shrub extract, against a panel of respiratory viruses. Drug Dev Res 1993, 28(4): 467-72.
38. Gilbert, B.E., Wyde, PR., Wilson, S.Z., Meyerson, L.R. SP-303 small-particle aerosol treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res 1993, 21(1): 37-45.
39. Wyde, PR., Ambrose, M.W., Meyerson, L.R., Gilbert, B.E. The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfluenza type 3 viruses in cotton rats. Antiviral Res 1993, 20(2): 145-54.
40. Barnard, D.L., Huffman, J.H., Meyerson, L.R., Sidwell, R.W. Mode of inhibition of respiratory syncytial virus by a plant flavonoid, SP-303. Chemotherapy 1993, 39(3): 212-7.
41. Barnard, D.L, Smee, D.F., Huffman, J.H., Meyerson, LR., Sidwell, R.W. Antiherpesvirus activity and mode of action of SP-303, a novel plant flavonoid. Chemotherapy 1993, 39(3): 203-11.
42. Crutchley, R.D., Miller, J., Garey, K.W. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother 2010, 44(5): 878-84.
43. Sidwell, R.W., Huffman, J.H., Moscon, B.J., Warren, R.P. Influenza virus-inhibitory effects of intraperitoneally and aerosol-administered SP-303, a plant flavonoid. Chemotherapy 1994, 40(1): 42-50.
44. A possible new drug to treat acute diarrhea from cholera and other conditions: crofelemer. National Institute of Allergy and Infectious Diseases, June 22, 2011. http://www.maid.nih.gov/topics/cholera/research/Pages/crofelemer. aspx. Accessed November 20, 2012.
45. Holodniy, M., Koch, J., Mistal, M., Schmidt, J.M., Khandwala, A., Pennington, J.E., Porter, S.B. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol 1999, 94(11): 3267-73.
46. DiCesare, D., DuPont, H.L., Mathewson, J.J., Ashley, D., Martinez-Sandoval, F, Pennington, J.E., Porter, S.B. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol 2002, 97(10): 2585-8.
47. MacArthur, R., Hawkins, T., Brown, S., LaMarca, A., Chaturvedi, P., Ernst, J. ADVENT trial: Crofelemer for the treatment of secretory diarrhea in HIV+ individuals. 19th Conf Retroviruses Opportunistic Infect (CROI) (March 5-8, Seattle) 2012, Abst 889.
48. Bardhan, P.K., Sharma, A., Bolmall, C, et al. Safety and efficacy of a novel anti-secretory anti-diarrheal agent Crofelemer (NP-303), in the treatment of adult acute infectious diarrhea and cholera, with or without the use of antibiotics. US-Japan CMSP: 13th Int Conf Emerging Infect Dis (EID) Pacific Rim (April 6-9, Kolkata, India) 2009
49. Approval of Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy. U.S. Food and Drug Administration, http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ HIVandAIDSActivities/ucm333826.htm. Accessed January 22, 2013.
50. Linton, DJ., Lau, L.C., Adaikan, PC Calcium-activated chloride channels in the corpus cavernosum: recent developments and future of a key cellular component of the erectile process. Int J Impot Res 2012, 24(6): 211-6.
51. Napo files for MUMS designation for crofelemer for chemotherapy-induced diarrhea in dogs [news release]. Napo Pharmaceuticals, Inc., September 12, 2012. www.napopharma.com/news/Napo-Files-for-MUMS-Desi gnation.pdf. Accessed November 20, 2012.